{"title":"Spatiotemporal analysis of small bowel capsule endoscopy videos for outcomes prediction in Crohn's disease.","authors":"Raizy Kellerman, Amit Bleiweiss, Shimrit Samuel, Reuma Margalit-Yehuda, Estelle Aflalo, Oranit Barzilay, Shomron Ben-Horin, Rami Eliakim, Eyal Zimlichman, Shelly Soffer, Eyal Klang, Uri Kopylov","doi":"10.1177/17562848231172556","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Deep learning techniques can accurately detect and grade inflammatory findings on images from capsule endoscopy (CE) in Crohn's disease (CD). However, the predictive utility of deep learning of CE in CD for disease outcomes has not been examined.</p><p><strong>Objectives: </strong>We aimed to develop a deep learning model that can predict the need for biological therapy based on complete CE videos of newly-diagnosed CD patients.</p><p><strong>Design: </strong>This was a retrospective cohort study. The study cohort included treatment-naïve CD patients that have performed CE (SB3, Medtronic) within 6 months of diagnosis. Complete small bowel videos were extracted using the RAPID Reader software.</p><p><strong>Methods: </strong>CE videos were scored using the Lewis score (LS). Clinical, endoscopic, and laboratory data were extracted from electronic medical records. Machine learning analysis was performed using the TimeSformer computer vision algorithm developed to capture spatiotemporal characteristics for video analysis.</p><p><strong>Results: </strong>The patient cohort included 101 patients. The median duration of follow-up was 902 (354-1626) days. Biological therapy was initiated by 37 (36.6%) out of 101 patients. TimeSformer algorithm achieved training and testing accuracy of 82% and 81%, respectively, with an Area under the ROC Curve (AUC) of 0.86 to predict the need for biological therapy. In comparison, the AUC for LS was 0.70 and for fecal calprotectin 0.74.</p><p><strong>Conclusion: </strong>Spatiotemporal analysis of complete CE videos of newly-diagnosed CD patients achieved accurate prediction of the need for biological therapy. The accuracy was superior to that of the human reader index or fecal calprotectin. Following future validation studies, this approach will allow for fast and accurate personalization of treatment decisions in CD.</p>","PeriodicalId":23022,"journal":{"name":"Therapeutic Advances in Gastroenterology","volume":"16 ","pages":"17562848231172556"},"PeriodicalIF":4.2000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9b/40/10.1177_17562848231172556.PMC10333642.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Gastroenterology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/17562848231172556","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
Background: Deep learning techniques can accurately detect and grade inflammatory findings on images from capsule endoscopy (CE) in Crohn's disease (CD). However, the predictive utility of deep learning of CE in CD for disease outcomes has not been examined.
Objectives: We aimed to develop a deep learning model that can predict the need for biological therapy based on complete CE videos of newly-diagnosed CD patients.
Design: This was a retrospective cohort study. The study cohort included treatment-naïve CD patients that have performed CE (SB3, Medtronic) within 6 months of diagnosis. Complete small bowel videos were extracted using the RAPID Reader software.
Methods: CE videos were scored using the Lewis score (LS). Clinical, endoscopic, and laboratory data were extracted from electronic medical records. Machine learning analysis was performed using the TimeSformer computer vision algorithm developed to capture spatiotemporal characteristics for video analysis.
Results: The patient cohort included 101 patients. The median duration of follow-up was 902 (354-1626) days. Biological therapy was initiated by 37 (36.6%) out of 101 patients. TimeSformer algorithm achieved training and testing accuracy of 82% and 81%, respectively, with an Area under the ROC Curve (AUC) of 0.86 to predict the need for biological therapy. In comparison, the AUC for LS was 0.70 and for fecal calprotectin 0.74.
Conclusion: Spatiotemporal analysis of complete CE videos of newly-diagnosed CD patients achieved accurate prediction of the need for biological therapy. The accuracy was superior to that of the human reader index or fecal calprotectin. Following future validation studies, this approach will allow for fast and accurate personalization of treatment decisions in CD.
背景:深度学习技术可以准确地检测和分级克罗恩病(CD)胶囊内窥镜(CE)图像上的炎症表现。然而,CE深度学习在CD中对疾病结果的预测效用尚未得到检验。目的:我们旨在开发一个深度学习模型,该模型可以根据新诊断的CD患者的完整CE视频来预测生物治疗的需求。设计:这是一项回顾性队列研究。研究队列包括在诊断6个月内进行CE (SB3, Medtronic)的treatment-naïve CD患者。使用RAPID Reader软件提取完整的小肠视频。方法:采用Lewis评分法对CE视频进行评分。从电子病历中提取临床、内窥镜和实验室数据。使用开发用于捕获视频分析的时空特征的TimeSformer计算机视觉算法进行机器学习分析。结果:患者队列包括101例患者。中位随访时间为902(354-1626)天。101例患者中有37例(36.6%)开始了生物治疗。TimeSformer算法训练和测试准确率分别达到82%和81%,ROC曲线下面积(Area under the ROC Curve, AUC)为0.86,预测生物治疗需求。相比之下,LS的AUC为0.70,粪钙保护蛋白的AUC为0.74。结论:对新诊断的CD患者的完整CE视频进行时空分析,可以准确预测是否需要生物治疗。准确度优于人类读数指数或粪便钙保护蛋白。在未来的验证研究中,这种方法将允许快速和准确地个性化CD的治疗决策。
期刊介绍:
Therapeutic Advances in Gastroenterology is an open access journal which delivers the highest quality peer-reviewed original research articles, reviews, and scholarly comment on pioneering efforts and innovative studies in the medical treatment of gastrointestinal and hepatic disorders. The journal has a strong clinical and pharmacological focus and is aimed at an international audience of clinicians and researchers in gastroenterology and related disciplines, providing an online forum for rapid dissemination of recent research and perspectives in this area.
The editors welcome original research articles across all areas of gastroenterology and hepatology.
The journal publishes original research articles and review articles primarily. Original research manuscripts may include laboratory, animal or human/clinical studies – all phases. Letters to the Editor and Case Reports will also be considered.